Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model

Journal of Alzheimer's Disease

Volumn 54, Issue 3, 2016, Pages 903-912

  Aso, Ester ^a,b   Andrés Benito, Pol ^a,b   Ferrer, Isidro ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Advanced stages; Alzheimer's disease; cannabidiol; dementia; 9 tetrahydrocannabinol

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; CANNABINOID; CANNABIS; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; PROTEIN; SYNAPTOTAGMIN; TETRAHYDROCANNABINOL; TXN2 PROTEIN; UNCLASSIFIED DRUG; WNT16 PROTEIN; 4 AMINOBUTYRIC ACID A RECEPTOR; AMPA RECEPTOR; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 2; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 3; MEDICAL CANNABIS;

ACTIVE AVOIDANCE TEST; AGED; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; GENOTYPE; GLIOSIS; HIPPOCAMPUS; MALE; MEMORY DISORDER; MOUSE; NEOCORTEX; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; HUMAN; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; DEMENTIA; DISEASE MODELS, ANIMAL; HUMANS; MALE; MEDICAL MARIJUANA; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, AMPA; RECEPTORS, GABA-A; TREATMENT OUTCOME;

EID: 84990052435     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160533     Document Type: Article

References (29)

1. Ferrer I (2012) Defining Alzheimer as acommonage-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 97, 38-51.
2. Selkoe DJ (2012) Preventing Alzheimer's disease. Science 337, 1488-1492.
3. Campbell VA, Gowran A (2007) Alzheimer's disease; taking the edge off with cannabinoids Br J Pharmacol 152, 655-662.
4. Koppel J, Davies P (2008) Targeting the endocannabinoid system in Alzheimer's disease. J Alzheimers Dis 15, 495-504.
5. Aso E, Ferrer I (2014) Cannabinoids for treatment of Alzheimer's disease: Moving toward the clinic. Front Pharmacol 5, 37.
6. Bedse G, Romano A, Lavecchia AM, Cassano T, Gaetani S (2015) The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease. J Alzheimers Dis 43, 1115-1136.
7. Lu HC, MackieK(2016) An introduction to the endogenous cannabinoid system. Biol Psychiatry 79, 516-525.
8. Aso E, Palomer E, Juvés S, Maldonado R, Muñoz FJ, Ferrer I (2012) CB1 agonist ACEA protects neurons and reduces the cognitive impairment of A-PP/PS1 mice. J Alzheimers Dis 30, 439-459.
9. Aso E, Juvés S, Maldonado R, Ferrer I (2013) CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A-PP/PS1 mice. J Alzheimers Dis 35, 847-858.
10. Martn-Moreno AM, Brera B, Spuch C, Carro E, Garca-Garca L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML (2012) Prolonged oral cannabinoid administration prevents neuroinflammation, lowers amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 9, 8.
11. Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M (2013) Activation of the CB(2) receptor system reverses amyloidinduced memory deficiency. Neurobiol Aging 34, 791-804.
12. Casarejos MJ, Perucho J, Gómez A, MuñozMP, Fernández-Estevez M, Sagredo O, Fernández Ruiz J, Guzmán M, de Yébenes JG, Mena MA (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 35, 525-539.
13. Aso E, Sánchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I (2015) Cannabis-based medicine reduces multiple pathological processes inA-PP/PS1 mice. J Alzheimers Dis 43, 977-991.
14. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945.
15. Reagan-ShawS, Nihal M, AhmadN(2008) Dose translation from animal to human studies revisited. FASEB J 22, 659-661.
16. Cheng D, Low JK, Logge W, Garner B, Karl T (2014) Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1-E9 mice. Psychopharmacology (Berl) 231, 3009-3017.
17. Cheng D, Spiro AS, Jenner AM, Garner B, Karl T (2014) Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. J Alzheimers Dis 42:1383-1396.
18. Chen R, Zhang J, Fan N, Teng ZQ, Wu Y, Yang H, Tang YP, Sun H, Song Y, Chen C (2013) -9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell 155, 1154-1165.
19. Mulder J, Zilberter M, Pasquare SJ, Alpar A, Schulte G, Ferreira SG, Kofalvi A, Martin-Moreno AM, Keimpema E, TanilaH, Watanabe M, Mackie K, Hortobagyi T, de Ceballos ML, Harkany T (2011) Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 134, 1041-1060.
20. Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G (2004) Differential effects of THC-or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47, 1170-1179.
21. Hoffman AF, Lupica CR (2013) Synaptic targets of -9-tetrahydrocannabinol in the central nervous system. Cold Spring Harb Perspect Med 3, 8.
22. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76, 70-81.
23. Ferrer I, Mart E, Tortosa A, Blasi J (1998) Dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and neurotransmission. J Neuropathol Exp Neurol 57, 218-225.
24. Kellner V, Menkes-Caspi N, Beker S, Stern EA (2014) Amyloid alters ongoing neuronal activity and excitability in the frontal cortex. Neurobiol Aging 35, 1982-1991.
25. D'Amelio M, RossiniPM(2012) Brain excitability and connectivity of neuronal assemblies in Alzheimer's disease: From animal models to human findings. Prog Neurobiol 99, 42-60.
26. Orr AL, Hanson JE, Li D, Klotz A, Wright S, Schenk D, Seubert P, Madison DV (2014) beta-amyloid inhibits E-S potentiation through suppression of cannabinoid receptor 1-dependent synaptic disinhibition. Neuron 82, 1334-1345.
27. Albayram O, Alferink J, Pitsch J, Piyanova A, Neitzert K, Poppensieker K, Mauer D, Michel K, Legler A, Becker A, Monory K, Lutz B, Zimmer A, Bilkei-Gorzo A (2011) Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging. Proc Natl Acad Sci U S A 108, 11256-11261.
28. Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S (2016) Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. Neurosci Biobehav Rev 64, 359-381.
29. Wade DT, Collin C, Stott C, Duncombe P (2010) Metaanalysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16, 707-714.